Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 2

Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation

Authors Muammer Kendirci, Emad Salem, Wayne JG Hellstrom

Published 15 May 2007 Volume 2007:3(2) Pages 277—289

Muammer Kendirci1, Emad Salem2, Wayne JG Hellstrom2

1Department of Urology, Sisli Etfal Training and Research Hospital, Istanbul, Turkey; 2Department of Urology, Tulane University Health Sciences Center, New Orleans, LA, USA

Abstract: Premature ejaculation (PE) is the most common male sexual disorder, estimated to affect up to 30% of men. Over the past one or two decades, clinical investigators have participated in an increasing number of studies that are helping in our understanding of PE, which will undoubtedly facilitate future treatments. Apart from a number of behavioral approaches, the treatment of PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors (SSRIs) via either on-demand or daily delivery. However, various undesirable side-effects of these medications have led researchers to search for and develop new therapeutic approaches for PE. Dapoxetine is a short-acting SSRI developed specifically for the treatment of PE. Early trials with dapoxetine have documented successful outcomes without serious short- or longterm side-effects. This review addresses the definition, classification, diagnosis, physiology, and neurobiopathology of PE, and evaluates therapeutic strategies with novel treatments for PE.

Keywords: dapoxetine, premature ejaculation, selective serotonin reuptake inhibitor, sildenafil, topical cream, paroxetine, fluoxetine, sertraline

Download Article [PDF] 

Readers of this article also read:

Fluoromica nanoparticle cytotoxicity in macrophages decreases with size and extent of uptake

Tee N, Zhu Y, Mortimer GM, Martin DJ, Minchin RF

International Journal of Nanomedicine 2015, 10:2363-2375

Published Date: 26 March 2015

Update on the treatment of ankylosing spondylitis

Walter P Maksymowych

Therapeutics and Clinical Risk Management 2007, 3:1125-1133

Published Date: 15 January 2008

Prevention of shingles: safety and efficacy of live zoster vaccine

Dianna Quan, Randall J Cohrs, Ravi Mahalingam, Donald H Gilden

Therapeutics and Clinical Risk Management 2007, 3:633-639

Published Date: 15 September 2007

The use of antithrombotics in patients presenting with stroke and atrial fibrillation

Carl Burgess, Tristram Ingham, Martin Woodbridge, Mark Weatherall, Michael Nowitz

Therapeutics and Clinical Risk Management 2007, 3:491-498

Published Date: 15 July 2007

Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia

Alberto Grossi, Francesca Balestri, Simone Santini

Therapeutics and Clinical Risk Management 2007, 3:269-275

Published Date: 15 May 2007

House dust mite control measures in the treatment of asthma

Gillian Vallance, Charles McSharry, Stuart Wood, Neil C Thomson

Therapeutics and Clinical Risk Management 2006, 2:347-354

Published Date: 15 December 2006